Ventricular arrhythmias are very common in the first few days after myocardial infarction and are a major cause of death. There is also a significant incidence of arrhythmias in the weeks and months after infarction (Norris et al., I968; Denborough et al., I968; Lawrie, I969; Sloman et al., 1970) . Intravenous lignocaine is helpful in the first few days, but no entirely satisfactory drug regimen has been established to prevent these later arrhythmias which occur at a time when oral treatment would be more appropriate. Procainamide has been shown to provide effective prophylaxis against ventricular arrhythmias during the acute phase of infarction I969) . It is usually well absorbed when taken orally (Mark et al., 1951; KochWeser, I97I) and is thus a feasible drug for longer term management after intravenous treatment is ended.
In this study procainamide was administered to patients who had developed ventricular arrhythmias requiring treatment with lignocaine in the immediate postinfarction period. Procainamide was started at the end of the lignocaine infusion period and was continued during convalescence in the general wards.
Koch-Weser and colleagues (Koch-Weser et successfully suppressed ventricular arrhythmias in the great majority of patients and were rarely associated with toxicity.
We have measured the plasma procainamide levels achieved with procainamide treatment during the hospital convalescent period.
Patients and methods
All the patients studied had been admitted to a coronary care unit. Myocardial infarction or ischaemia had been diagnosed on the basis of clinical history, electrocardiograms, and serial estimations of cardiac enzymes. Left heart failure was judged to be present if characteristic features were present in the chest x-ray.
In each case a ventricular arrhythmia had been observed during monitoring and treated by lignocaine. In a few cases additional antiarrhythmic drugs had been required. Arrhythmias classified as requiring lignocaine therapy were: ventricular fibrillation, ventricular tachycardia, and ventricular ectopic beats which were multifocal, 'R on T ', in a sequence of 2 or more, or occurring more frequently than 5 a minute. Ventricular arrhythmias associated with a slow sinus rate and abolished by atropine were not included in this classification.
Procainamide dosage
Procainamide therapy was started at dosages that were based on body weight. Patients weighing 5o-9o kg were given a loading dose of i g followed 4 hours later by maintenance doses of 375 mg every 4 hours throughout the day and night. The maintenance dose was subse-quently increased or decreased if indicated by clinical response or recorded plasma procainamide level. The i g oral loading dose was given at I .0oo hours: this was 3 hours after a light breakfast and I hour before lunch. The lignocaine infusion was stopped about i hour after the loading dose had been given. The average time between admission and start of procainamide was 4-7 days (range .
The majority of patients were transferred to the general medical wards within 24 hours of the start of procainamide administration.
Blood for plasma procainamide estimation was taken at i and 4 hours after the loading dose. The accuracy of the method was assessed by blind estimation of samples to which a known amount of procainamide had been added. Assays of samples containing 4-O, 5-o, and 7-5 stg/ml gave mean levels (± SD) of 4.33±o-o8, 5-26±0o05., and 7.35±O'O5 jig/ml, respectively. The metabolites para-aminobenzoic acid and paraacetobenzoic acid were tested and found not to interfere. Lignocaine and heparin were not detected by the assay. Recovery of procainamide by the extraction process was I00 per cent.
All plasma levels are expressed as procainamide base. Fig. i shows the plasma procainamimde levels recorded at frequent intervals after a I g dose. Peak levels The personal data of these patients are included in the Table. There was a wide range of levels attained in patients using the same dosage. There was a weak and statistically insignificant correlation between the 4-hour procainamide level group.bmj.com on June 25, 2017 -Published by http://heart.bmj.com/ Downloaded from therapy and the body weight (Fig. 4) . This was also the case when patients with raised blood urea were excluded. There was also a poor correlation between the procainamide level and the blood urea. Fig. 5 The time to reach this 'steady state' depends on the elimination rate of the drug. With procainamide this steady state will be reached within 24 hours by most patients: those with very delayed procainamide excretion may require up to 48 hours. The procainamide level should be measured after i or 2 days administration and the dosage then adjusted if necessary to individual needs.
Results

Absorption curves
A major disadvantage of procainamide is its rapid elimination from the body. In subjects with normal renal function its mean half-life is approximately 3 5 hours (Koch-Weser, I97I). Fig. 6 illustrates the dilemma in formulating an oral dosage regimen for such a short acting drug when absorption is rapid. If the total daily dose is kept constant but the interval between doses prolonged, ineffective plasma levels are reached before the next dose. If the dosage interval is constant but the size of each dose increased to avoid low concentrations, then the consequently higher peak levels may cause toxicity if, like procainamide (Koch-Weser, I97I), the drug is rapidly distributed to the tissues. To keep the drug levels within the relatively narrow effective range it becomes necessary to administer doses at very frequent intervals. Koch-Weser et al. (I969) have used a 3-hourly administration regimen but we felt this was unsuitable for use in the convalescent period. Even with a 4-hourly regimen, we had initially found it very difficult to ensure regular administration of doses in general medical wards. The importance of accurately timed doses was emphasized to ward staff and the regularity of administration had greatly improved by the time this study began. However, a 4-hourly regimen is vulnerable to disruption by the patient's absence from the ward, e.g. for x-rays, and many patients found that the night time procainamide dose disturbed their sleep to a troublesome extent. We now consider a 4-hourly regimen unsatisfactory for routine prophylactic use.
The use of procainamide would be improved if a satisfactory slow release preparation was available or if a chemical modification could be made to prolong the half-life of elimination. At present the frequent administration of adequate doses based on plasma drug level measurements is the surest way of maintaining a satisfactory antiarrhythmic effect.
